Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Adjunctive therapy in community-acquired pneumonia
Richard G Wunderink
Medicine, Pulmonary Division
Research output
:
Contribution to journal
›
Review article
›
peer-review
18
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Adjunctive therapy in community-acquired pneumonia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adjunctive Therapy
100%
Community-acquired Pneumonia
100%
Sepsis
40%
Clinical Trials
20%
Recombinant
20%
United States
20%
Prospective Randomized Trial
20%
Improved Outcomes
20%
Leading Causes of Death
20%
Antibiotics
20%
Cause of Death
20%
Immunomodulatory Effect
20%
Most Common Cause
20%
Therapeutic Measures
20%
Acute Lung Injury
20%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
20%
Antibiotic-free
20%
Delayed Diagnosis
20%
Severe Pneumonia
20%
Oxygenation
20%
Surfactant Replacement Therapy
20%
Severe Community-acquired Pneumonia
20%
Coagulation System
20%
Exogenous Surfactant
20%
Corticosteroid Treatment
20%
Statin Use
20%
Tissue Factor Pathway inhibitor-2 (TFPI-2)
20%
Pneumonia Detection
20%
Macrolide Antibiotics
20%
Drotrecogin Alfa
20%
Medicine and Dentistry
Adjuvant Therapy
100%
Community-Acquired Pneumonia
100%
Sepsis
33%
Recombinant Tissue Factor Pathway Inhibitor
33%
Antibiotics
33%
Blood Clotting
16%
Infection
16%
Nonsteroid Antiinflammatory Agent
16%
Acute Lung Injury
16%
Statin
16%
Corticosteroid Therapy
16%
Drotrecogin Alfa
16%
Clinical Trial
16%
Macrolide
16%
Surfactant
16%
Nursing and Health Professions
Community Acquired Pneumonia
100%
Adjuvant Therapy
100%
Recombinant Tissue Factor Pathway Inhibitor
33%
Sepsis
33%
Statin (Protein)
16%
Oxygenation
16%
Infection
16%
Nonsteroid Antiinflammatory Agent
16%
Acute Lung Injury
16%
Corticosteroid Therapy
16%
Drotrecogin
16%
Macrolide
16%
Surfactant
16%
Pharmacology, Toxicology and Pharmaceutical Science
Community Acquired Pneumonia
100%
Antibiotics
33%
Recombinant Tissue Factor Pathway Inhibitor
33%
Sepsis
33%
Macrolide
16%
Clinical Trial
16%
Acute Lung Injury
16%
Infection
16%
Statin (Protein)
16%
Non-Steroidal Anti-Inflammatory Drug
16%
Surfactant
16%
Drotrecogin
16%